EGFR and neurodegenerative disease: Afatinib, an orally available EGFR tyrosine kinase inhibitor, inhibits EGFR activation to alleviate neuroinflammation by reducing caspase 1 activation and interleukin-1β levels in neurodegenerative diseases (Chen et al., 2019).